scholarly journals Atypically Located Basal Cell Carcinoma: Three Case Reports

2020 ◽  
Vol 42 (3) ◽  
Author(s):  
Ebru KARAGUN ◽  
Mehmet GAMSİZKAN ◽  
Yavuz EYUP ◽  
Atike BAHCİVAN ◽  
Yunus OZCAN ◽  
...  
Keyword(s):  
Basal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Basal Cell ◽  
Case Reports

Metastatic Basal Cell Carcinoma: Four Case Reports, Review of Literature, and Immunohistochemical Evaluation

2006 ◽  
Vol 130 (1) ◽  
pp. 45-51
Author(s):  
Diana N. Ionescu ◽  
Muammar Arida ◽  
Drazen M. Jukic
Keyword(s):  
Basal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Basal Cell ◽  
Case Reports ◽  
Small Sample ◽  
Ki 67 ◽  
Immunohistochemical Markers ◽  
Metastatic Basal Cell Carcinoma ◽  
Metastatic Sites

Abstract Context.—Metastatic basal cell carcinoma (BCC) is relatively rare and is seldom considered a complication in the routine treatment and follow-up of patients with BCC. Although multiple studies have tried to distinguish aggressive from nonaggressive BCCs, to our knowledge, no consistent clinical, histopathologic, or immunohistochemical features have yet been reported. Objective.—To report 4 cases of metastatic BCCs and to evaluate these in addition to known nonmetastatic BCCs with specific immunostains in an attempt to find distinct morphologic or immunohistochemical patterns that could be helpful in identifying aggressive BCCs. Design.—We reviewed 4 cases of metastatic BCCs and recorded the clinical and morphologic findings. We then searched our archives for 14 cases of BCC that followed the usual nonaggressive course. We evaluated these 18 cases with immunohistochemical stains for Ki-67, p53, and bcl-2. Results.—In metastasizing BCC, Ki-67 staining was slightly higher in metastatic sites than in primary sites (average 63% and 51%, respectively). p53 was expressed in 3 of 4 primary sites and 2 of 4 metastatic sites. Bcl-2 was positive in both primary and metastatic sites in 3 of 4 cases. In the 14 cases of nonaggressive BCC, staining for Ki-67 averaged 38%, p53 was positive in 11 cases, and Bcl-2 staining was noted in 13 cases. Conclusions.—Overall, in the small sample that we evaluated, the immunohistochemical markers for Ki-67, p53, and Bcl-2 did not distinguish between metastatic and nonaggressive BCCs.

scholarly journals Successful basal cell carcinoma defect reconstruction using combination of rotation and advancement flap: Two case reports

2021 ◽  
Vol 13 (2) ◽  
Author(s):  
Khairuddin Djawad ◽  
Siswanto Wahab ◽  
Airin Nurdin
Keyword(s):  
Basal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Basal Cell ◽  
Case Reports ◽  
Skin Flap ◽  
Advancement Flap ◽  
Surrounding Tissue ◽  
Transposition Flap ◽  
High Tension ◽  
Excisional Surgery

Defects resulting from surgical procedure may be challenging to reconstruct depending on the size and location. In case of large defects, primary closure is often not possible and thus requires skin flap or graft. In such cases, skin flap is advantageous as it produces a similar color and texture with the surrounding tissue. Skin flap techniques such as advancement flap, rotation flap dan transposition flap are useful in closing small defects. In moderate to large-sized defects, especially in areas with high tension, a combination of more than one type of flap might be necessary. This report describes two cases of large defects on the temple and cheek following basal cell carcinoma excisional surgery which were successfully closed using a combination of rotation and advancement flaps. Both patients showed excellent functional and cosmetic outcome.

scholarly journals Use of reflectance confocal microscopy to diagnose occult basal cell carcinoma: 2 case reports

2018 ◽  
Vol 4 (6) ◽  
pp. 599-601 ◽  
Author(s):  
Simone Cappilli ◽  
Francesca Perino ◽  
Valeria Coco ◽  
Alessandro Di Stefani ◽  
Ketty Peris
Keyword(s):  
Confocal Microscopy ◽  
Basal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Basal Cell ◽  
Case Reports ◽  
Reflectance Confocal Microscopy

Efficacy and safety of IO103 a novel anti PD-L1 vaccine in basal cell carcinoma.

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e22070-e22070
Author(s):  
Nicolai Grønne Jørgensen ◽  
Jeanette Kaae ◽  
Jacob Handlos Grauslund ◽  
Özcan Met ◽  
Inge Marie Svane ◽  
...  
Keyword(s):  
Basal Cell Carcinoma ◽  
Partial Response ◽  
Immune Responses ◽  
Cell Carcinoma ◽  
Basal Cell ◽  
Molecular Mechanisms ◽  
Case Reports ◽  
Peptide Vaccine ◽  
Target Lesion ◽  
Clinical Responses

e22070 Background: Basal cell carcinoma (BCC) is the most frequent malignancy. Case reports have described effect of immune checkpoint blocking antibodies (ICB) against PD-1 in BCC (Cannon et al. 2018, Chang et al. 2017, Ikeda et al. 2016, Winkler et al. 2017). Autoimmune side effects of ICB are well known and limits a wider use in BCC. IO103 is a peptide vaccine against major programmed death (PD) ligand 1 (PD-L1). In a first-in-man study of IO103 in patients with multiple myeloma (NCT03042793) regression of co-existing BCC was observed in two patients which prompted the current study. Methods: A single arm phase IIa study of subcutaneous IO103 (q2w six times followed optionally by q4w an additional 3 times) with the adjuvant Montanide for patients with BCC (NCT03714529). Eligible patients had at least one biopsy verified BCC suitable for sequential biopsies, and no severe autoimmune comorbidity. The primary endpoints were categorical clinical responses of target tumors, percent change in largest diameter of target tumor and immune responses to the vaccine. Secondary endpoint was safety. One tumor per patient was designated target tumor, if more than one tumor the remaining were designated non-target tumors. Only target tumors were sequentially biopsied during vaccinations. Results: Ten patients were included at the department of Dermatology, Herlev and Gentofte Hospital, Denmark between November 19th, 2018 and October 21st, 2019. Based on target lesion assessment, one patient achieved partial response. Two additional patients achieved CR in non-target lesions, including one lesion that had recurred after previous surgery. Categorical clinical responses are given in table. Adverse events were max CTCAE Grade 2 and related events were only CTCAE Grade 1 reversible reactions. Vaccine induced immune responses against PD-L1 were detected in blood samples from eight of ten patients and vaccine specific skin-infiltrating lymphocytes from five of eight tested patients. Conclusions: In this exploratory study, one target tumor achieved partial response. Nonetheless, the two clearances and one partial response of non-target tumors suggest that IO103 may be effective against BCCs. The vaccine was well tolerated. Understanding the underlying molecular mechanisms would be needed to select patients for further studies with IO103. Clinical trial information: NCT03714529. [Table: see text]

scholarly journals A Vismodegib Experience in Elderly Patients with Basal Cell Carcinoma: Case Reports and Review of the Literature

2020 ◽  
Vol 21 (22) ◽  
pp. 8596
Author(s):  
Anna Passarelli ◽  
Giovanna Galdo ◽  
Michele Aieta ◽  
Tommaso Fabrizio ◽  
Antonio Villonio ◽  
...  
Keyword(s):  
Basal Cell Carcinoma ◽  
Elderly Patients ◽  
Cell Carcinoma ◽  
Basal Cell ◽  
Safety Profile ◽  
Hedgehog Signaling ◽  
Case Reports ◽  
Locally Advanced ◽  
Human Tumor ◽  
Efficacy And Safety

Cutaneous basal cell carcinoma (BCC) is the most common type of human tumor, and its incidence rate is increasing worldwide. Up until a few years ago, therapeutic options have been limited for patients with advanced BCC (including metastatic and locally-advanced BCC). Over the last few years, promising systemic therapies have been investigated for the treatment of advanced BCC. In particular, the Hedgehog signaling inhibition has shown remarkable results for this population. Hedgehog inhibitors, represented by vismodegib and sonidegib, have been approved by the Food and Drug Administration and the European Medicines Agency for the treatment of both locally advanced and metastatic BCC, with, generally, a good safety profile. Notwithstanding the late onset of BCC in the global population, associated with life expectancy increase, only a few clinical trials have evaluated the efficacy and safety profile of Hedgehog inhibitors in this complex and neglected population. Herein, we review the major mechanisms implicated in the pathogenesis of BCC focusing on the Hedgehog signaling pathway and its therapeutic role in the elderly population. Finally, we report two case reports of BCC elderly patients in order to demonstrate both efficacy and safety of the Hedgehog inhibitors.

scholarly journals Vulvar Basal Cell Carcinoma: Four Case Reports With Immunohistochemical Study

2017 ◽  
Vol 21 (5) ◽  
pp. 457-459 ◽  
Author(s):  
Mª Reyes García-de-la-Fuente ◽  
Maria Santacana ◽  
Felip Vilardell ◽  
R. M. Pujol ◽  
Eloi Gari ◽  
...  
Keyword(s):  
Stem Cells ◽  
Basal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Basal Cell ◽  
Immunohistochemical Study ◽  
Case Reports ◽  
Basal Cell Carcinomas

Basal cell carcinomas (BCC) are the most frequent tumours in humans and normally appear in photoexposed areas of the skin. It is widely accepted that BCCs originate at follicular stem cells and consequently are very rare in nonhairy areas. Here, we report 4 cases of vulvar BCC, 3 of which were located in a vulvar semimucous area, a nonphotoexposed area, and a nonhairy area. We have determined the CK7 and CK19 profile of all cases; both are markers of simple epithelium with glandular differentiation. Interestingly, all cases were positively stained for CK7 and CK19. Considering that the vulvar region is rich in sebaceous and apocrine units, we hypothesise a glandular origin of BCCs situated in the vulvar region.

Sign in / Sign up

Export Citation Format

Share Document